Skip to main content
ARCT
NASDAQ Life Sciences

Arcturus Q3 10-Q: Loss Narrows to $7.4M, $184.8M Cash, CSL Exit Booked

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$9.9
Mkt Cap
$266.04M
52W Low
$5.5
52W High
$17.96
52W Position info
80% above low
Off High info
45% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ARCT sits 80% above its 52-week low of $5.5.

Summary

Arcturus' Q3 10-Q confirms the narrowed $7.4M net loss and $184.8M cash balance already reported, and for the first time lays out the full economics of the CSL Seqirus termination and the closed myNEO acquisition.


Key Events · Earnings and Guidance · ARCT

  • Q3 Loss Narrows on Cost Cuts

    Net loss was $7.4M ($0.26/share) versus $13.4M ($0.49/share) a year earlier, as R&D fell 27% to $17.0M from $23.3M. Nine-month net loss widened to $58.2M from $36.7M.

  • Cash Down $46.1M Year to Date

    Cash and equivalents were $184.8M at September 30, 2026 versus $230.9M at December 31, 2025; nine-month operating cash use was $46.3M. Management cites runway through year-end 2028.

  • CSL Exit Economics Quantified

    The August 3, 2026 termination brought a $12.0M cash payment and release of ~$16.0M in R&D credit and unspent development repayment obligations; the ICC arbitration was dismissed and $16.8M of CSL revenue was recognized in Q3.

  • myNEO Deal Closed October 15

    Arcturus paid ~$5.0M cash and issued 361,355 unregistered shares, with up to $20.0M of contingent clinical and collaboration milestones, a portion settleable in stock.


Analysis · ARCT · Life Sciences

The headline numbers were already out via the same-day 8-K and press release, but the 10-Q is where the balance sheet and the CSL Seqirus exit become concrete. Cash fell to $184.8M from $230.9M at year-end 2025 — a $46.3M nine-month operating burn — and management still frames runway through year-end 2028, which assumes the cost base stays near the newly reduced level (R&D down 27% year over year to $17.0M in the quarter). The CSL termination is now fully quantified: $12.0M cash in, roughly $16.0M of R&D credit and repayment obligations released, the ICC arbitration dismissed, and $16.8M of revenue recognized in Q3 — which is why the quarter shows revenue growth despite the collaboration ending. Against that, the company has taken on new obligations: single-digit royalties to CSL on future vaccine sales, up to $20.0M of contingent myNEO milestones (partly payable in stock), and up to $80.0M of Thermo Fisher/PPD service commitments for ARCT-032. The $200M ATM remains unused this year, so the dilution lever is intact but unpulled.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARCT was trading at $9.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $266M. The 52-week trading range was $5.50 to $17.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARCT - Latest Insights

ARCT
Nov 16, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.52
Real-time Price: $7.55 info
Change: -$0.970 (-11%) info
Market Cap: $214.728M info
ARCT
Nov 05, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.34
Real-time Price: $7.55 info
Change: -$1.79 (-19%) info
Market Cap: $214.728M info
ARCT
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.80
Real-time Price: $7.55 info
Change: -$6.25 (-45%) info
Market Cap: $214.728M info
ARCT
Sep 23, 2026, 4:29 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $7.55 info
Change: -$6.35 (-46%) info
Market Cap: $214.728M info
ARCT
Sep 23, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $7.55 info
Change: -$6.35 (-46%) info
Market Cap: $214.728M info